4749 N.E 11th Avenue
29 articles with BioStem Technologies
ProcessPro, leading ERP software solution company, is pleased to announce that BioStem Technologies, Inc. has chosen ProcessPro's Global ERP solution to streamline and optimize their biopharmaceutical manufacturing, API repackaging and pharmaceutical reformulation operations.
Maxim will focus on assisting BioStem Technologies with its strategies for maximizing shareholder value through its full scope of investment banking services.
Shares of Pompano Beach, Fla.-based BioStem Technologies are down more than 6 percent this morning following the company’s announcement it has launched a new life sciences subsidiary, the Amnion Division of BioStem Life Sciences focused on the development of amniotic tissue-based therapies.
BioStem Technologies, Inc. (BSEM) Launches New Subsidiary to Engage in the Processing and Supply of Regenerative Tissue Products
BioStem Technologies, Inc. has launched a new subsidiary under its Life Sciences division, which will engage in the business of supplying Amnion based PHSA 361 products.
BioStem Technologies, Inc. has announced that it has implemented an expanded shareholder communications initiative to provide improved clarity into BioStem's business plans, upcoming research and development, drug approvals and growth strategy.
The stocks of approximately 10,000 companies are traded daily in the multi-tiered OTC Markets, but only companies in the top tier qualify to trade on the OTCQX. T
Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy.
BioStem Technologies announced today, the hiring of Larry Jones, as Chief Revenue Officer.
BioStem Technologies Announces the Engagement of Investment Banking Firm Young America Capital for $15M 06(c) Offering
The $15 million offering will be open not only to individual accredited investors, but also to qualified institutional buyers.
Dr. Sandqvist is a leading neurologist in Sweden, but maintains a residence in Ft Lauderdale and has been involved with the Company for more than a year as a shareholder and advisor.
BioStem Technologies Announces the Addition of University of Miami Professor Brant D. Watson, Ph.D., to the Company’s Scientific Advisory Board
Dr. Watson’s research was funded by the National Institute of Neurological Diseases and Stroke for 22 years.
BioStem Technologies Launches SEO Optimized Website and Facility Expansion to Include Schedule III-V DEA Product Storage
The company has begun expansion of its facility to 4,500 square feet.
BioStem Technologies Announces Letter Of Intent With Watermakers, Inc. To Begin Testing On Staniel Cay In The Exuma Cays, Bahamas
BioStem Technologies Announces Issuance Of Prescription Drug Repackager Permit For Qualified Pharma Ingredients Inc.
BioStem Technologies Acquires Their First FDA Approved Branded Generic Drug (ANDA) -- Granisol Oral Solution